KAILERA THERAPEUTICS INC
KLRANASDAQTrading Snapshot
- Day Range
- $10.89 – $11.07
- 52-Week Range
- $10.83 – $28.23
- Volume
- $2.66B
- Avg Volume
- $2.72B
- Shares Outstanding
- 129.6M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $166M
- Last Q Revenue
- $41M
- P/E Ratio
- -6.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.86
- Dividend Yield
- 0.00%
Why Investors Own KLRA
- ✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KAILERA THERAPEUTICS INC
KLRA
StockOtter · stockotter.spaceAbout KAILERA THERAPEUTICS INC
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6%
Kailera Therapeutics to Participate in September Investor Conferences
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA
Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ: KLRA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commi
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.
2 GLP-1 Stocks That Could Double Your Money by 2031
They are fairly risky, but their potential upside is massive.
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mi